» Authors » E J P de Koning

E J P de Koning

Explore the profile of E J P de Koning including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 561
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Nijhoff M, Engelse M, Dubbeld J, Braat A, Ringers J, Roelen D, et al.
Am J Transplant . 2015 Aug; 16(1):246-53. PMID: 26288226
Pancreatic islet transplantation is performed in a select group of patients with type 1 diabetes mellitus. Immunosuppressive regimens play an important role in long-term islet function. We aimed to investigate...
12.
Ellenbroek J, Tons H, Westerouen van Meeteren M, de Graaf N, Hanegraaf M, Rabelink T, et al.
Diabetologia . 2013 Jun; 56(9):1980-6. PMID: 23771206
Aims/hypothesis: Incretin-based therapies improve glycaemic control in patients with type 2 diabetes. In animal models of diabetes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) increase beta cell mass. GLP-1RAs are also evaluated...
13.
Khairoun M, de Koning E, van den Berg B, Lievers E, de Boer H, Schaapherder A, et al.
Am J Transplant . 2013 Feb; 13(5):1272-81. PMID: 23433125
Simultaneous pancreas-kidney transplantation (SPK) is an advanced treatment option for type 1 diabetes mellitus (DM) patients with microvascular disease including nephropathy. Sidestreamdarkfield (SDF) imaging has emerged as a noninvasive tool...
14.
de Boer H, Hovens M, van Oeveren-Rietdijk A, Snoep J, de Koning E, Tamsma J, et al.
Arterioscler Thromb Vasc Biol . 2010 Oct; 31(2):408-15. PMID: 21030714
Objective: The presence of kinase-insert domain-containing receptor (KDR) on circulating CD34+ cells is assumed to be indicative for the potential of these cells to support vascular maintenance and repair. However,...
15.
Cnop M, Hughes S, Igoillo-Esteve M, Hoppa M, Sayyed F, van de Laar L, et al.
Diabetologia . 2009 Oct; 53(2):321-30. PMID: 19855953
Aims/hypothesis: Defects in pancreatic beta cell turnover are implicated in the pathogenesis of type 2 diabetes by genetic markers for diabetes. Decreased beta cell neogenesis could contribute to diabetes. The...
16.
van Wijk J, Cabezas M, Coll B, Joven J, Rabelink T, de Koning E
Atherosclerosis . 2005 Sep; 186(1):152-9. PMID: 16137694
Objective: We postulated that in type 2 diabetes, the postprandial phase is a pro-inflammatory state that can be modulated by PPAR-gamma agonists. For this purpose, we determined the effects of...
17.
Da Silva J, Jacobs J, Kirwan J, Boers M, Saag K, Ines L, et al.
Ann Rheum Dis . 2005 Aug; 65(3):285-93. PMID: 16107513
Adverse effects of glucocorticoids have been abundantly reported. Published reports on low dose glucocorticoid treatment show that few of the commonly held beliefs about their incidence, prevalence, and impact are...
18.
van Wijk J, Cabezas M, de Koning E, Rabelink T, van der Geest R, Hoepelman I
J Clin Endocrinol Metab . 2005 Mar; 90(6):3575-82. PMID: 15784707
The use of antiretroviral combination therapy in HIV has been associated with lipodystrophy and several metabolic risk factors. We postulated that patients with HIV-lipodystrophy have impaired adipose tissue free fatty...
19.
Losekoot M, Broekman A, Breuning M, de Koning E, Romijn J, Maassen J
Ned Tijdschr Geneeskd . 2005 Feb; 149(3):139-43. PMID: 15693590
Objective: To describe the results of mutation analysis of the genes involved in maturity onset diabetes of the young (MODY) types 1-3. Design: Descriptive. Method: In the period July 2000-October...
20.
van Oostrom A, Sijmonsma T, Verseyden C, Jansen E, de Koning E, Rabelink T, et al.
J Lipid Res . 2003 Feb; 44(3):576-83. PMID: 12562833
Atherosclerosis is a low-grade inflammatory disease involving leukocytes, lipids, and glucose leading to endothelial dysfunction. Since activation of neutrophils by triglycerides and glucose has been described in vitro, we hypothesized...